Loading...
•
Dec 31, 2024
Twist Bioscience Q1 2025 Earnings Report
Reported record revenue and improved gross margin.
Key Takeaways
Twist Bioscience reported a strong start to fiscal year 2025, achieving record revenue of $88.7 million, a 24% increase compared to the same period last year, and a gross margin of 48.3%, which is a 7.8 margin points improvement year-over-year.
Total revenue for the first quarter of fiscal 2025 grew to $88.7 million, a 24% increase compared to the same period in fiscal 2024.
Gross margin for the first quarter of fiscal 2025 increased to 48.3% compared to 40.5% for the same period in fiscal 2024.
Net loss attributable to common stockholders for the first quarter of fiscal 2025 was $31.6 million, or $0.53 per share, compared to $43.0 million, or $0.75 per share, for the same period of fiscal 2024.
As of December 31, 2024, the company had $270.8 million in cash, cash equivalents and short-term investments.
Twist Bioscience
Twist Bioscience
Twist Bioscience Revenue by Segment
Revenue by Segment
SynBio Revenue
CapyFin.comNGS Revenue
CapyFin.comBiopharma Revenue
CapyFin.com Forward Guidance
Twist Bioscience expects revenue in the range of $372 million to $379 million for full year fiscal 2025 and expects gross margin over 50% for 4QFY25.
Positive Outlook
- Total revenue to be in the range of $372 million to $379 million compared to the previous guidance of $367 million to $377 million, indicating growth of 19 to 21 percent year over year
- SynBio revenue of $144 million to $147 million, compared to previous guidance of $142 million to $146 million, growth of 17 to 18 percent
- NGS revenue of $205 million to $209 million, compared to previous guidance of $204 million to $209 million, growth of 21 to 24 percent
- Biopharma revenue of $23 million, compared to previous guidance of $21 million to $22 million, growth of 13 percent
- Gross margin is projected to be approximately 49% for fiscal 2025 with quarterly sequential improvements, compared to previous guidance of 48% and 4QFY25 gross margin is projected to be over 50%
Challenges Ahead
- Adjusted EBITDA of approximately $(55) million to $(60) million for fiscal 2025 compared to previous guidance of $(60) million to $(65) million
- Total revenue of approximately $91 million to $93 million for the second quarter
- SynBio revenue of approximately $35.5 million to $36 million for the second quarter
- NGS revenue of approximately $50 million to $51 million for the second quarter
- Biopharma revenue of approximately $5.5 million to $6.0 million for the second quarter
Revenue & Expenses
Visualization of income flow from segment revenue to net income